- Home
- ACTG vs NGNE Comparison
ACTG vs NGNE Comparison
Compare ACTG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTG
- NGNE
- Stock Information
- Founded
- ACTG 1993
- NGNE 2003
- Country
- ACTG United States
- NGNE United States
- Employees
- ACTG N/A
- NGNE N/A
- Industry
- ACTG Multi-Sector Companies
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- ACTG Miscellaneous
- NGNE Health Care
- Exchange
- ACTG Nasdaq
- NGNE Nasdaq
- Market Cap
- ACTG 363.5M
- NGNE 213.2M
- IPO Year
- ACTG 1996
- NGNE N/A
- Fundamental
- Price
- ACTG $3.77
- NGNE $22.26
- Analyst Decision
- ACTG
- NGNE Strong Buy
- Analyst Count
- ACTG 0
- NGNE 7
- Target Price
- ACTG N/A
- NGNE $41.86
- AVG Volume (30 Days)
- ACTG 179.5K
- NGNE 218.2K
- Earning Date
- ACTG 08-07-2025
- NGNE 08-08-2025
- Dividend Yield
- ACTG N/A
- NGNE N/A
- EPS Growth
- ACTG N/A
- NGNE N/A
- EPS
- ACTG N/A
- NGNE N/A
- Revenue
- ACTG $222,414,000.00
- NGNE $925,000.00
- Revenue This Year
- ACTG $141.36
- NGNE N/A
- Revenue Next Year
- ACTG N/A
- NGNE N/A
- P/E Ratio
- ACTG N/A
- NGNE N/A
- Revenue Growth
- ACTG 65.22
- NGNE N/A
- 52 Week Low
- ACTG $2.70
- NGNE $6.88
- 52 Week High
- ACTG $5.70
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- ACTG 52.62
- NGNE 62.94
- Support Level
- ACTG $3.68
- NGNE $19.01
- Resistance Level
- ACTG $4.02
- NGNE $18.21
- Average True Range (ATR)
- ACTG 0.13
- NGNE 1.77
- MACD
- ACTG 0.02
- NGNE 0.41
- Stochastic Oscillator
- ACTG 50.00
- NGNE 93.15
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.